Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
ID:
Password:
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

Agents/Distributors
 Regional Subscription Agents/Distributors
 
Current Topics in Pharmacology   Volumes    Volume 25 
Abstract
Acute effect of atorvastatin in comparison with rosuvastatin on glucose homeostasis in hypercholesteremic patients
Hani M. Almukhtar, Ibrahim M. Faisal, Marwan M Merkhan
Pages: 25 - 34
Number of pages: 10
Current Topics in Pharmacology
Volume 25 

Copyright © 2021 Research Trends. All rights reserved

ABSTRACT
 
Short-term in vitro experiments provide evidence that lipophilic statin blocks KATP channel which may improve insulin secretion, whereas, short incubation with hydrophilic statins has no effect on KATP channel. The present study aimed at observing the early effect of atorvastatin and rosuvastatin on glucose levels of prediabetic patients with hypercholesterolemia given the well-established difference in lipophilicity of these two statins. In the present study, thirty-five prediabetic patients with hypercholesterolemia were randomly allocated to 2 groups atorvastatin (n = 20) and rosuvastatin (n = 15); each patient received 20 mg per day of either treatment for 6-weeks. Serum levels of fasting blood sugar (FBS) and glycated hemoglobin (HbA1c) were analyzed before and after 6-weeks of administration. Besides significant improvement in lipid profile, atorvastatin consumption for 6-weeks significantly reduced serum levels of FBG (107.6 mg/dl ± 1.326 vs basal 124.5 mg/dl ± 1.381; P = 0.001) and HbA1c (5.616% ± 0.1039 vs basal 6.413% ± 0.1277 P < 0.0001). Similarly, rosuvastatin reduced FBG (109.6 mg/dl ± 3.124 6 vs basal 123.6 mg/dl ± 1.536), and HbA1c (5.075% ± 0.1181 vs basal 5.925% ± 0.1548). However, there was no statistically significant difference between atorvastatin and rosuvastatin on FBG and HbA1c after 6-weeks treatment. In conclusion, both atorvastatin and rosuvastatin exert early improvement in plasma glucose in prediabetic patients with hypercholesterolemia. Further and more powered studies are needed to confirm this observation in diabetic patients; moreover, the studies should include groups on long-term therapy with statin to improve the quality of the result and to reduce the limitation of short-durations.
View Full Article  


 
search


E-Commerce
Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Login
Search Products
Browse in Alphabetical Order : Journals
Series/Books
Browse by Subject Classification : Journals
Series/Books

Miscellaneous
Ordering Information Ordering Information
Downloadable forms Downloadable Forms